Literature DB >> 32857836

Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers.

Myron M Levine1, Salim Abdullah2, Yaseen M Arabi3, Delese Mimi Darko4, Anna P Durbin5, Vicente Estrada6, Euzebiusz Jamrozik7, Peter G Kremsner8,9, Rosanna Lagos10, Punnee Pitisuttithum11, Stanley A Plotkin12, Robert Sauerwein13, Sheng-Li Shi14, Halvor Sommerfelt15, Kanta Subbarao16, John J Treanor17, Sudhanshu Vrati18, Deborah King19, Shobana Balasingam20, Charlie Weller21, Anastazia Older Aguilar22, M Cristina Cassetti23, Philip R Krause24,25, Ana Maria Henao Restrepo26.   

Abstract

WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a "rescue treatment" to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; adult volunteers; challenge model; experimental challenge

Year:  2021        PMID: 32857836      PMCID: PMC7499532          DOI: 10.1093/cid/ciaa1290

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Research ethics and public trust in vaccines: the case of COVID-19 challenge trials.

Authors:  Nir Eyal
Journal:  J Med Ethics       Date:  2022-05-20       Impact factor: 5.926

2.  Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Authors:  Ben Killingley; Alex J Mann; Mariya Kalinova; Alison Boyers; Niluka Goonawardane; Jie Zhou; Kate Lindsell; Samanjit S Hare; Jonathan Brown; Rebecca Frise; Emma Smith; Claire Hopkins; Nicolas Noulin; Brandon Löndt; Tom Wilkinson; Stephen Harden; Helen McShane; Mark Baillet; Anthony Gilbert; Michael Jacobs; Christine Charman; Priya Mande; Jonathan S Nguyen-Van-Tam; Malcolm G Semple; Robert C Read; Neil M Ferguson; Peter J Openshaw; Garth Rapeport; Wendy S Barclay; Andrew P Catchpole; Christopher Chiu
Journal:  Nat Med       Date:  2022-03-31       Impact factor: 87.241

3.  Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research.

Authors:  Stanley M Spinola; Camilla Broderick; Gregory D Zimet; Mary A Ott
Journal:  Open Forum Infect Dis       Date:  2020-12-28       Impact factor: 3.835

4.  Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.

Authors:  Caroline Barker; Katharine Collet; Diane Gbesemete; Maria Piggin; Daniella Watson; Philippa Pristerà; Wendy Lawerence; Emma Smith; Michael Bahrami-Hessari; Halle Johnson; Katherine Baker; Ambar Qavi; Carmel McGrath; Christopher Chiu; Robert C Read; Helen Ward
Journal:  Wellcome Open Res       Date:  2022-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.